ArticleRSC medicinal chemistry2023
Design, synthesis and immunological evaluation of monophosphoryl lipid A derivatives as adjuvants for a RBD-hFc based SARS-CoV-2 vaccine.
Shiwei Su, Liqing Chen, Menglan Yang, Dan Liang, Bixia Ke, Zhongqiu Liu, Changwen Ke, Guochao Liao, Liang Liu, Xiang Luo
Open access · greenAbstract read
In one paragraphArticle in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors at 2 institutions in 1 country.
Shiwei SuJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine Guangzhou China liao@gzucm.edu.cn luoxiang@gzucm.edu.cn.
Liqing ChenJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine Guangzhou China liao@gzucm.edu.cn luoxiang@gzucm.edu.cn.
Menglan YangJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine Guangzhou China liao@gzucm.edu.cn luoxiang@gzucm.edu.cn.
Dan LiangGuangdong Provincial Center for Disease Control and Prevention Guangzhou China.
Bixia KeGuangdong Provincial Center for Disease Control and Prevention Guangzhou China.
Zhongqiu LiuJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine Guangzhou China liao@gzucm.edu.cn luoxiang@gzucm.edu.cn.
Changwen KeGuangdong Provincial Center for Disease Control and Prevention Guangzhou China.
Guochao LiaoJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine Guangzhou China liao@gzucm.edu.cn luoxiang@gzucm.edu.cn.ORCID https://orcid.org/0000-0001-6112-5040 Liang LiuState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou China lliu@gzucm.edu.cn.
Xiang LuoJoint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine Guangzhou China liao@gzucm.edu.cn luoxiang@gzucm.edu.cn.
Guangzhou University of Chinese Medicine · CNGuangdong Provincial Center for Disease Control and Prevention · CN
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Toll-like receptor 4 (TLR4) is a reliable target for the development of vaccine adjuvants. To identify novel TLR4 ligands with improved immunological properties for use as adjuvants for a RBD-hFc based SARS-CoV-2 vaccine, herein, natural
Identifiers
PMID36760743
PMCPMC9890559
OpenAlexW4311809566
What OpenQuestion holds
Textmetadata
Read underepoch 390